


Amendments to the Claims:

This listing of claims will replace all prior versions, and listing, of claims in the application:

Claims 1-21 (Cancelled).

Claim 22 (New): A method of inhibiting MetAP2 in mammals, comprising administering to a mammal an effective amount of a compound of formula (IA) or a pharmaceutically acceptable salt or solvate thereof:



Formula (IA)

wherein:

X is S;

R¹ is optionally substituted furan-C₀₋₆alkyl;

R² is optionally substituted Ar-C₀₋₆alkyl; and

R³ is H, optionally substituted C₁₋₆alkyl, C₃₋₆alkenyl, or C₃₋₆alkynyl.

Claim 23 (Original): The method of claim 1, wherein the compound of formula (IA) is selected from:

3-anilino-5-(furan-2-ylthio)-1,2,4-triazole;

5-(5-phenylamino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;

5-(5-phenylamino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;

3-anilino-5-(furan-3-ylthio)-1,2,4-triazole;

3-(4-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;

5-(5-*p*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;

5-(5-*p*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;

3-(4-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;

3-(2-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;

5-(5-*o*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;

5-(5-*o*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;

3-(2-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;

3-(2-methoxy-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;

5-(5-(2-methoxyphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;

3-(2-methoxy-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(2-isopropyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(2-isopropylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(2-isopropyl amino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(2-isopropyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(3-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(3-methylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(3-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(4-fluoro-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(4-fluorophenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(4-fluorophenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(4-fluoro-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
or a pharmaceutically acceptable salt or solvate thereof.

Claim 24 (New): The method of claim 22, wherein the compound of formula (IA) is selected from:

5-(5-phenylamino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-phenylamino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
5-(5-*p*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-*p*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
5-(5-*o*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-*o*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(2-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(2-methoxy-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(2-methoxyphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester
3-(2-methoxy-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
5-(5-(3-methylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(3-methylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(4-fluoro-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(4-fluorophenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(4-fluorophenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(4-fluoro-anilino)-5-(furan-3-ylthio)-1,2,4-triazole

or a pharmaceutically acceptable salt or solvate thereof.


Claim 25 (New): The method of claim 22, wherein the compound of formula (IA) is selected from:

3-anilino-5-(furan-3-ylthio)-1,2,4-triazole;
3-anilino-5-(furan-2-ylthio)-1,2,4-triazole;
3-(2-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
3-(3-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
3-(3-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole; and
or a pharmaceutically acceptable salt or solvate thereof.

Claim 26 (New): The method of claim 22, wherein the compound of formula (IA) is selected from:

3-(2-isopropyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(2-isopropylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(2-isopropyl amino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(2-isopropyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(4-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
3-(4-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
or a pharmaceutically acceptable salt or solvate thereof.

Claim 27 (New): A method for treating a disease mediated by MetAP2 in mammals, comprising administering to a mammal in need of such treatment, an effective amount of a compound of formula (IA) or a pharmaceutically acceptable salt or solvate thereof:



Formula (IA)

wherein:

X is S;
R¹ is optionally substituted furan-C₀₋₆alkyl;
R² is optionally substituted Ar-C₀₋₆alkyl; and
R³ is H, optionally substituted C₁₋₆alkyl, C₃₋₆alkenyl, or C₃₋₆alkynyl.

Claim 28 (New): The method of claim 27, wherein the compound of formula (IA) is selected from:

3-anilino-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-phenylamino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-phenylamino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-anilino-5-(furan-3-ylthio)-1,2,4-triazole;
3-(4-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-*p*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-*p*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(4-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(2-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-*o*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-*o*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(2-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(2-methoxy-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(2-methoxyphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
3-(2-methoxy-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(2-isopropyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(2-isopropylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(2-isopropyl amino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(2-isopropyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(3-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(3-methylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(3-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(4-fluoro-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(4-fluorophenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(4-fluorophenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(4-fluoro-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
or a pharmaceutically acceptable salt or solvate thereof.

Claim 29 (New): The method of claim 27, wherein the compound of formula (IA) is selected from:

5-(5-phenylamino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-phenylamino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
5-(5-*p*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;

5-(5-*p*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
5-(5-*o*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-*o*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(2-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(2-methoxy-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(2-methoxyphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester
3-(2-methoxy-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
5-(5-(3-methylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(3-methylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(4-fluoro-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(4-fluorophenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(4-fluorophenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(4-fluoro-anilino)-5-(furan-3-ylthio)-1,2,4-triazole
or a pharmaceutically acceptable salt or solvate thereof.


Claim 30 (New): The method of claim 27, wherein the compound of formula (IA) is selected from:

3-anilino-5-(furan-3-ylthio)-1,2,4-triazole;
3-anilino-5-(furan-2-ylthio)-1,2,4-triazole;
3-(2-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
3-(3-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
3-(3-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole; and
or a pharmaceutically acceptable salt or solvate thereof.

Claim 31 (New): The method of claim 27, wherein the compound of formula (IA) is selected from:

3-(2-isopropyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(2-isopropylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(2-isopropyl amino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(2-isopropyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(4-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
3-(4-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
or a pharmaceutically acceptable salt or solvate thereof.

Claim 32 (New): A method of treating conditions mediated by angiogenesis, selected from cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity, comprising administering a compound of formula (IA):



Formula (IA)

wherein:

X is S;

R¹ is optionally substituted furan-C₀₋₆alkyl;

R² is optionally substituted Ar-C₀₋₆alkyl; and

R³ is H, optionally substituted C₁₋₆alkyl, C₃₋₆alkenyl, or C₃₋₆alkynyl.

Claim 33 (New): The method of claim 32, wherein the compound of formula (IA) is selected from:

3-anilino-5-(furan-2-ylthio)-1,2,4-triazole;

5-(5-phenylamino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;

5-(5-phenylamino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;

3-anilino-5-(furan-3-ylthio)-1,2,4-triazole;

3-(4-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;

5-(5-*p*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;

5-(5-*p*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;

3-(4-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;

3-(2-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;

5-(5-*o*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;

5-(5-*o*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;

3-(2-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;

3-(2-methoxy-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;

5-(5-(2-methoxyphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;

3-(2-methoxy-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;

3-(2-isopropyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;

5-(5-(2-isopropylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;

5-(5-(2-isopropyl amino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(2-isopropyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(3-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(3-methylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(3-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(4-fluoro-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(4-fluorophenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(4-fluorophenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(4-fluoro-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
or a pharmaceutically acceptable salt or solvate thereof.

Claim 34 (New): The method of claim 32, wherein the compound of formula (IA) is selected from:

5-(5-phenylamino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-phenylamino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
5-(5-*p*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-*p*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
5-(5-*o*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-*o*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(2-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(2-methoxy-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(2-methoxyphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester
3-(2-methoxy-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
5-(5-(3-methylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(3-methylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(4-fluoro-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(4-fluorophenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(4-fluorophenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(4-fluoro-anilino)-5-(furan-3-ylthio)-1,2,4-triazole
or a pharmaceutically acceptable salt or solvate thereof.


Claim 35 (New): The method of claim 32, wherein the compound of formula (IA) is selected from:

3-anilino-5-(furan-3-ylthio)-1,2,4-triazole;
3-anilino-5-(furan-2-ylthio)-1,2,4-triazole;
3-(2-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
3-(3-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
3-(3-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole; and
or a pharmaceutically acceptable salt or solvate thereof.

Claim 36 (New): The method of claim 32, wherein the compound of formula (IA) is selected from:

3-(2-isopropyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(2-isopropylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(2-isopropyl amino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(2-isopropyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(4-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
3-(4-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
or a pharmaceutically acceptable salt or solvate thereof.

Claim 37 (New): A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof:



Formula (I)

wherein:

X is S;

R¹ is optionally substituted furan-C₀₋₆alkyl;

R² is optionally substituted Ar-C₀₋₆alkyl; and

R³ is H, optionally substituted C₁₋₆alkyl, C₃₋₆alkenyl, or C₃₋₆alkynyl,

provided that the compound is not 5-anilino-3-benzylthio-1,2,4-triazole,

3-(4-methyl-anilino)-5-benzylthio-1,2,4-triazole,

3-(2-methyl-anilino)-5-benzylthio-1,2,4-triazole,

3-(4-methoxy-anilino)-5-benzylthio-1,2,4-triazole,

3-(2-methoxy-anilino)-5-benzylthio-1,2,4-triazole, or
3-ethyl-3-anilino-5-benzylthio-1,2,4-triazole.

Claim 38 (New): A pharmaceutical composition comprising a compound as claimed in claim 37 and a pharmaceutically acceptable carrier.

Claim 39 (Original): The compound of claim 37 which is selected from:

5-(5-phenylamino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-phenylamino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
5-(5-*p*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-*p*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
5-(5-*o*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-*o*-tolyl amino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(2-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(2-methoxy-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(2-methoxyphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester
3-(2-methoxy-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
5-(5-(3-methylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(3-methylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(4-fluoro-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(4-fluorophenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(4-fluorophenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde; and
3-(4-fluoro-anilino)-5-(furan-3-ylthio)-1,2,4-triazole
or a pharmaceutically acceptable salt or solvate thereof.

Claim 40 (New): The compound of claim 37 which is selected from:


3-anilino-5-(furan-3-ylthio)-1,2,4-triazole;
3-anilino-5-(furan-2-ylthio)-1,2,4-triazole;
3-(2-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
3-(3-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
3-(3-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole; and
or a pharmaceutically acceptable salt or solvate thereof.

Claim 41 (New): The compound of claim 37 which is selected from:


3-(2-isopropyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
5-(5-(2-isopropylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;
5-(5-(2-isopropyl amino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;
3-(2-isopropyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
3-(4-methyl-anilino)-5-(furan-2-ylthio)-1,2,4-triazole;
3-(4-methyl-anilino)-5-(furan-3-ylthio)-1,2,4-triazole;
or a pharmaceutically acceptable salt or solvate thereof.

Claim 42 (New): A method of making a compound of formula (I), wherein X is sulfur, comprising the steps of:


- a) combining an isothiocyanate of Formula (II):




with thiourea to provide a compound of Formula (III):




- b) treating the compound of Formula (III) with an alkyl halide under basic conditions provide a compound of Formula (IV):



- c) treating the compound of formula (IV) with hydrazine to provide a compound of formula (V):




- d) treating the compound of formula (V) with an alkyl halide under basic conditions to provide a compound of formula (VI):




Formula (VI)

e) protecting the compound of formula (VI) to provide a compound of formula (VII):




Formula (VII)

f) alkylating the compound of formula (VII) with an alkyl halide to provide a compound of formula (VIII):



Formula (VIII)

g) deprotecting the compound of formula (VIII) to provide the compound of formula (I):



Formula (I)

wherein:

X is S;

R¹ is optionally substituted furan-C₀-₆alkyl;

R² is optionally substituted Ar-C₀-₆alkyl; and

R³ is H, optionally substituted C₁-₆alkyl, C₃-₆alkenyl, or C₃-₆alkynyl, provided that the compound is not 5-anilino-3-benzylthio-1,2,4-triazole, 3-(4-methyl-anilino)-5-benzylthio-1,2,4-triazole, 3-(2-methyl-anilino)-5-benzylthio-1,2,4-triazole, 3-(4-methoxy-anilino)-5-benzylthio-1,2,4-triazole, 3-(2-methoxy-anilino)-5-benzylthio-1,2,4-triazole, or 3-ethyl-3-anilino-5-benzylthio-1,2,4-triazole.